Georgia Bio Names South Forsyth High School Junior as 2022 Georgia BioGENEius Winner

Mokshith Mannuru Advances to International Competition Against Top Students

Georgia Bio and the BioEd Institute named  Mokshith Mannuru , a junior at South Forsyth High School in Cumming, GA, as the winner of the 2022 Georgia BioGENEius Challenge. The BioGENEius Challenge is the premier competition for high school students that recognizes outstanding research and innovation in the biotechnology field. As Georgia’s BioGENEius finalist, Mokshith will attend the 2022 International BioGENEius competition, which will be held during the 2022 BIO International Convention, the industry’s trade conference from June 13-16 in San Diego, CA. There he will engage with leading companies, scientists and innovators currently transforming the scientific landscape and gain valuable insights into an industry making significant contributions to the world.

While in San Diego, Mokshith will compete against high school students from the U.S., Canada, and Germany in the International BioGENEius Challenge. The student projects will represent a range of biotechnology topics such as healthcare, agriculture, and the environment.

Mokshith’s project uses bioinformatics to identify the common function of genes that are related to Autism Spectrum Disorder (ASD). Over 1,000 genes are evidenced to contribute to ASD but are not understood well enough to use genetics in diagnosing or treating ASD. Mokshith hypothesized that these genes contribute to human development and would therefore affect development if a copy of the gene were faulty. He used data from the International Mouse Phenotyping Consortium (IMPC) to observe the phenotypes of mice where the ASD genes that are also found in mice were knocked out (deleted). The missing genes were found to strongly affect development or behavior, or lead to embryonic lethality. ASD patients would have one mutated copy of a gene related to ASD and one normal copy. This research suggests several pathways and development processes that attribute to ASD and could be used to validate ASD mouse models that are used in biomedical research.

“The level of competition in Georgia was at an all-time high this year,” said Georgia Bio President and CEO Maria Thacker. “Georgia Bio is thrilled to have Mokshith represent our state on the international stage at the upcoming BIO Convention, and we are proud to support this Georgia scholar in his future endeavors.”

Georgia Bio also congratulates the Georgia BioGENEius runner-up,  Varun Sendilraj ,who is a senior at Lambert High School in Suwanee, GA. Varun developed a mobile app, DFUCare, which uses deep-learning algorithms to diagnose, analyze and monitor Diabetic Foot Ulcers (DFU) in diabetes patients. DFU is a major complication of diabetes mellitus that can lead to amputation and mortality if left untreated. Caring for DFU can be expensive and time consuming, which limits treatment options for many patients around the globe. DFUCare quantifies the size of wounds, performs tissue analysis, and detects healing potential over time. It can also allow doctors and patients to share medical reports with experts, saving time and resources for treating diabetic foot ulcers.

Judging the 2022 Georgia BioGENEius Challenge were Jamie L. Graham, Boehringer Ingelheim; Ralph L. Cordell, CDC; Ian Biggs, UGA; and Alex Harvey, ViaMune, Inc.

“I am amazed at the quality and thoughtfulness of the projects on display,” said Ian Biggs of UGA’s Innovation Gateway. “The insights displayed, and the obvious effort put into the projects is way beyond my expectations.”

National and International winners will be announced after the competition. See the  International BioGENEius website  for more information on the 2022 schedule. Winners will receive cash scholarships.

Follow the BioGENEius Challenge:  Throughout the challenge, @BiotechInstitut will be tweeting interviews, photos, and engaging with the biotechnology community by using the hashtag #BioGENEius.

About the Biotechnology Institute

The Biotechnology Institute is an independent, national nonprofit organization dedicated to education about the present and future impact of biotechnology. Its mission is to engage, excite and educate the public, particularly students and teachers, about biotechnology and its immense potential for solving human health, food and environmental problems. For more information, visit  www.biotechinstitute.org.

About the BioEd Institute

The BioEd Institute, a division of the 501(c)(3) nonprofit the Center for Global Health Innovation, works to strengthen Georgia’s life sciences workforce pipeline through classroom-to-career initiatives that align with industry needs. BioEd works closely with its sister organization Georgia Bio, which serves the state’s life science industry. For more information about BioEd, visit them online at  www.georgiabioed.org , or on Facebook (@GeorgiaBioEd), Twitter (@georgiabioed), or LinkedIn (@georgia-bioed).

Contacts

Kristin Boscan
585.943.8699
kboscan@cghi.org

Biotech Leaders Launch National Alliance to Define the Future of American Innovation

May 5, 2026
New coalition forms to develop a national innovation roadmap to strengthen and extend  America’s global leadership in biotechnology

UGA & Manus Among Awardees in $214M BioMADE Investment

April 30, 2026
BioMADE Announces $21.4 Million Invested in 14 Projects to Develop the U.S. Bioindustrial Manufacturing Industry and Advance National Security Priorities

Nutrivert announces first close on $6 million Series A-2 funding round

April 17, 2026
April 17, 2026 - Nutrivert Inc., a developer of non-antibiotic replacements for antibiotic growth promoters in livestock, today announced it has completed the first close, raising $2.375 million, of its Series A-2 funding round of $6 million. The round was led by global animal health investor Arrow Ventures with participation from other investors. The funding will be used to further develop Nutrivert’s manufacturing, human food safety and target animal safety and efficacy packages for the company’s lead product Nutrivert LDPP. Nutrivert LDPP is a proprietary, novel, orally available, lipidated synthetic enantiomeric desmuramyl analog of muramyl dipeptide, the smallest conserved immunoactive component of bacterial peptidoglycan. LDPP has no antibacterial effect but has consistently promoted growth and improved feed efficiency in pig studies. LDPP binds to the mammalian NOD2 receptor and is the only NOD2 ligand reported to inhibit the inflammatory signal NF-κB. In pilot studies, LDPP rescued 70kg pigs from an otherwise lethal dose of porcine reproductive and respiratory syndrome virus (PRRSV) and abrogated influenza disease symptoms in piglets. The Company intends to develop LDPP for all major livestock species worldwide. Patents have been granted in most major markets. The global antibiotic growth promoter market is worth an estimated $5.8 billion. Approximately 73% of all antibiotics are fed to livestock. The market is believed to be the world’s largest drug market by volume, with ~100,000 tons of active pharmaceutical ingredient administered annually. FDA’s latest data, for 2024, show a 13% rise in U.S. livestock antibiotic use since 2017. The Food and Agriculture Organization reports that livestock antibiotics are mostly given to speed animal growth. Regulators and non-governmental organizations have called for reduction of antibiotic use in livestock, citing concerns that the global, intensive use of antibiotics, often at subtherapeutic doses, selects for antimicrobial resistance: bacteria that are “immune” to antibiotics and that therefore pose a threat to public health. Spillovers of antibiotic-resistant bacteria from livestock to humans have been documented. “Nutrivert LDPP has consistently improved feed efficiency in pigs without antibiotics,” said Bernhard Kaltenboeck, CSO. “We are excited to have the support of Arrow Ventures and our other investors in bringing a new tool that will help producers reduce production costs and reduce selection pressure for antimicrobial resistance.” About Nutrivert LDPP: LDPP is an investigational compound currently undergoing clinical evaluation. It has not been approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other global regulatory authority for any indication. The safety and efficacy of LDPP have not been established. Any mention of potential use is based on preliminary data and does not guarantee future regulatory clearance or commercial availability.
MORE POSTS